Pharma & Biotech Global Week in Review 28 April 2010 from IP Think Tank

Here is Think IP Strategy’s weekly selection of top Pharma & Biotech intellectual property news breaking in the blogosphere and internet.

Please join the discussion by adding your comments on any of these stories, and please do let us know if you think we’ve missed something important, or if there is a source you think should be monitored.

You can separately subscribe to the IP Think Tank Global Week in Review at the Subscribe page: http://thinkipstrategy.com/subscribe/

 
Highlights this week included:

Kenya High Court suspends Anti-Counterfeiting Act ‘in as far as it applies to generic medicines’ (Afro-IP) (Michael Geist)

India: Roche and Tarceva in Delhi HC again, this time vs Natco (Spicy IP) (Generic Pharmaceuticals and IP)

Ecuador: Compulsory license granted to Cipla for Lopinavir + Ritonavir (Generic Pharmaceuticals and IP) (IP Watch)

 
General

The best life sciences patent litigators in the world revealed (IAM)

Geneva events address public health solutions for developing countries (IP Watch)

Panellists see critical moment for international policy on biodiversity and trade (IP Watch)

Medicrime: Another anti-counterfeiting convention emerges in Europe (IP Watch)

Graham Dutfield on traditional medicines and patents – excerpts from the talk (Spicy IP)

EU: SPCs on adjuvants?? (The SPC Blog)

EU: Originator drug companies hit by European ruling: C-62/09 Association of the British Pharmaceutical Industry (Managing Intellectual Property)

EU: EPO – Convention on Biological Diversity and the exception to patentability for inventions which are contrary to ‘ordre public’ or morality (EPLAW)

India: Patent office releases details on pharmaceutical product patents granted in last 3 years (Generic Pharmaceuticals and IP) (Spicy IP)

Kenya: High Court suspends Anti-Counterfeiting Act ‘in as far as it applies to generic medicines’ (Afro-IP) (Michael Geist)

Romania: SPC fees and forms (The SPC Blog)

US: Post-Wyeth PTA calculation errors? (Anticipate This!)

US: MPEG LA announces formation of gene patent pool (Patent Docs)

US: In an amended complaint, plaintiff adds count of false marking where defendants allegedly marked products with plaintiff’s patent number: Tripharma LLC v. Solstice International Partners et al (Docket Report)

US: FTC annual report highlights the Commission’s patent settlement efforts (FDA Law Blog)

 
Products

Adcirca (Tadalafil) – US: Declaratory judgement of non-infringement and invalidity based on ANDA to manufacture generic Adcirca: Synthon v Eli Lilly et al (Patent Docs)

Amrix (Cyclobenzaprine) – US: Mylan seeks declaratory judgment of noninfringement, unenforceability and invalidity of Amrix patent, based on Mylan’s ANDA to manufacture generic version (Patent Docs)

Aplenzin (Buproprion) – US: Patent infringement complaint following Para IV challenge: Biovail Laboratories v Watson Pharmaceuticals (Patent Docs)

Eletone – US: Patent infringement complaint filed over sale of PruVel product: Ferndale v PruGen (Patent Docs)

Intuniv (Guanfacine) – US: Shire sues Teva for patent infringement in response to its ANDA submission (The IP Factor)

Kaletra (Lopinavir, Ritonavir) – Ecuador: Compulsory license granted to Cipla for Lopinavir + Ritonavir (Generic Pharmaceuticals and IP) (IP Watch)

Nexavar (Sorafenib) – India: Bayer v Cipla hearing held 23 April – some thoughts (Generic Pharmaceuticals and IP)

Opana (Oxymorphone) – US: Patent infringement complaint following Para IV challenge: Endo Pharmaceuticals v Roxane Laboratories (Patent Docs)

OsteoCel – US: Patent infringement complaint files based on defendant’s manufacture and sale of competing product: Nuvasive, Inc. et al. v. Orthofix International N.V. et al. (Patent Docs)

Prilosec (Omeprazole) – US: Dr Reddy’s wins attorney’s fees from AstraZeneca in Prilosec OTC case (Orange Book Blog)

Protonix (Pantoprazole) – US: Jury finds Protonix patent infringed by Teva (The IP Factor)

Restasis (Ciclosporin) – Restasis royalty dispute finally settles (IP finance)

Tarceva (Erlotinib) – India: Roche and Tarceva in Delhi HC again, this time vs Natco (Spicy IP) (Generic Pharmaceuticals and IP)

Viagra (Sildenafil) – Austria: Settlement in Styriagra/Viagra trade mark dispute (IPKat)

 

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: